Search research articles
Contact Us
Filters
Showing results (31-40 of 59) with videos related to
Page
of 6
Sort By:
Cureus
|
March 9, 2026
Implementation of a Multidisciplinary Guideline to Reduce Post-operative Acute Kidney Injury in Elective Surgical Patients: A Quality Improvement Study
Joseph Sciacca, Stephen Pearlman, Marcin Jankowski, et al.
Child & Youth Care Forum
|
April 6, 2026
The feasibility, acceptability, and preliminary outcomes of a brief behavioral parenting group program delivered through telehealth
Jacob B W Holzman, Sarah Taylor-Cavelier, Jessica L Hawks, et al.
Gynecologic Oncology
|
April 28, 2026
Endometrial cancer: A Society of Gynecologic Oncology evidence-based review and recommendations: Part I
Renata Urban, Tara Castellano, Kemi Doll, et al.
Oncotarget
|
March 5, 2016
Impact of molecular profiling on overall survival of patients with advanced ovarian cancer
Thomas J Herzog, David Spetzler, Nick Xiao, et al.
Gynecologic Oncology
|
December 24, 2013
A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study
Lainie P Martin, Michael Sill, Mark S Shahin, et al.
Gynecologic Oncology
|
June 12, 2022
Overall survival in patients with FIGO stage IVA cervical cancer
Joshua P Schiff, Rachel Mintz, Alexander C Cohen, et al.
Plos One
|
May 2, 2015
Incorporation of porcine adenovirus 4 fiber protein enhances infectivity of adenovirus vector on dendritic cells: implications for immune-mediated cancer therapy
Ivy Wilkinson-Ryan, Julius Kim, Sojung Kim, et al.
Gynecologic Oncology
|
July 30, 2020
Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study
Krishnansu S Tewari, Michael W Sill, Robert L Coleman, et al.
Cancer
|
December 21, 2023
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer
Bobbie J Rimel, Danielle Enserro, David P Bender, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology
|
February 15, 2013
Reversal of mitochondrial proteomic loss in Type 1 diabetic heart with overexpression of phospholipid hydroperoxide glutathione peroxidase
Walter A Baseler, Erinne R Dabkowski, Rajaganapathi Jagannathan, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 59) with videos related to
Sort By:
Page
of 6
Cureus
|
March 9, 2026
Implementation of a Multidisciplinary Guideline to Reduce Post-operative Acute Kidney Injury in Elective Surgical Patients: A Quality Improvement Study
Joseph Sciacca, Stephen Pearlman, Marcin Jankowski, et al.
Child & Youth Care Forum
|
April 6, 2026
The feasibility, acceptability, and preliminary outcomes of a brief behavioral parenting group program delivered through telehealth
Jacob B W Holzman, Sarah Taylor-Cavelier, Jessica L Hawks, et al.
Gynecologic Oncology
|
April 28, 2026
Endometrial cancer: A Society of Gynecologic Oncology evidence-based review and recommendations: Part I
Renata Urban, Tara Castellano, Kemi Doll, et al.
Oncotarget
|
March 5, 2016
Impact of molecular profiling on overall survival of patients with advanced ovarian cancer
Thomas J Herzog, David Spetzler, Nick Xiao, et al.
Gynecologic Oncology
|
December 24, 2013
A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study
Lainie P Martin, Michael Sill, Mark S Shahin, et al.
Gynecologic Oncology
|
June 12, 2022
Overall survival in patients with FIGO stage IVA cervical cancer
Joshua P Schiff, Rachel Mintz, Alexander C Cohen, et al.
Plos One
|
May 2, 2015
Incorporation of porcine adenovirus 4 fiber protein enhances infectivity of adenovirus vector on dendritic cells: implications for immune-mediated cancer therapy
Ivy Wilkinson-Ryan, Julius Kim, Sojung Kim, et al.
Gynecologic Oncology
|
July 30, 2020
Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study
Krishnansu S Tewari, Michael W Sill, Robert L Coleman, et al.
Cancer
|
December 21, 2023
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer
Bobbie J Rimel, Danielle Enserro, David P Bender, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology
|
February 15, 2013
Reversal of mitochondrial proteomic loss in Type 1 diabetic heart with overexpression of phospholipid hydroperoxide glutathione peroxidase
Walter A Baseler, Erinne R Dabkowski, Rajaganapathi Jagannathan, et al.
Page
of 6